Wesana Health Holdings Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

26.9%

Wachstumsrate der Gewinne

68.8%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	23.1%
Wachstumsrate der Einnahmen	-136.9%
Eigenkapitalrendite	n/a
Netto-Marge	n/a
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie Wesana Health Holdings Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

CNSX:WESA.X Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Umsatz	Allgemeine und Verwaltungskosten
31 Mar 24	-2	1
31 Dec 23	-2	1
30 Sep 23	-3	2
30 Jun 23	0	0
31 Mar 23	-1	1
31 Dec 22	-3	3
30 Sep 22	-2	4
30 Jun 22	-2	4
31 Mar 22	-6	5
31 Dec 21	-6	5
30 Sep 21	-6	3
30 Jun 21	-8	4
31 Mar 21	-3	1
31 Dec 20	0	0

Wesana Health Holdings Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Third quarter 2022 earnings released: EPS: US$0.019 (vs US$0.12 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.42 loss in 2Q 2021)

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

New major risk - Negative shareholders equity

High number of new and inexperienced directors

High number of new and inexperienced directors

New major risk - Negative shareholders equity

Wesana Health Holdings Inc., Annual General Meeting, Jun 09, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.019 (vs US$0.12 loss in 3Q 2021)

Less than half of directors are independent

Wesana Health Holdings Inc. Announces Departure of Meghana A. Gaeta as Chief Marketing Officer

APS Innovations LLC acquired Advanced Psychiatric Management LLC from Wesana Health Holdings Inc. (CNSX:WESA) for USD 2.1 million.

Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.42 loss in 2Q 2021)

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Wesana Health Holdings Inc. Announces Resignation of Chad Bronstein as Executive Chairman

Wesana Health Holdings Outlines Accelerated Drug Development Pathway

Less than half of directors are independent

Wesana Explores Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder

Wesana Health Announces Positive Findings from Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol

Wesana Health Holdings Inc. Grants US FDA Pre-IND Meeting for SANA-013

Wesana Health Holdings Inc. Files Patent Cooperation Treaty Patent Applications Towards Securing the Exclusive Rights to Protocols

Wesana Health Holdings Inc. (CNSX:WESA) acquired Advanced Psychiatric Management LLC.

Wesana Health Holdings Inc. (CNSX:WESA) completed the acquisition of PsyTech Inc.

Board Member recently bought CA$209k worth of stock

Wesana Health Holdings Inc. (CNSX:WESA) entered into a definitive agreement to acquire PsyTech Inc. for CAD 20.4 million.

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren